Matrix-M™ adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial. The trial will evaluate ...

Younis, MA, Alsogaihi, MA, Abdellatif, AAH and Saleem, I Nanoformulations in the Treatment of Lung Cancer: Current Status and Clinical Potential. Drug Development and Industrial Pharmacy. ISSN ...

Such nanolasers have been researched and developed for some time. However, KTU scientists’ version is unique in terms of its ...

Scientists have developed a unique nanolaser. Although the dimensions of this laser are so small that its structure can only be seen through a powerful microscope, its potential is vast. With ...

The Cloud Microservices market is projected to grow from USD 7.5 billion in 2024 to USD 22.1 billion by 2031, at a compound annual growth rate (CAGR) of 17.0%. This growth is driven by the increasing ...

Lithuania researchers, and scientists from Japan have developed a unique nanolaser. Although the dimensions of this laser are ...

Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse ...

The UB physics professor’s nanomaterials work has applications in quantum information, renewable energy, biomedicine and more.

UVa researchers have developed a polymer that defies traditional trade-offs between stiffness and stretchability, enabling ...

Dr. Damya Laoui (VIB-VUB): "It is great to see that our strategy to use LNPs to administer therapeutic mRNAs into the tumor, works. It stimulates the immune system to recognize and eliminate cancer ...

Singerman Real Estate acquired an empty lab building on the Illinois Science & Technology Park campus for a fraction of its ...